Lexicon Pharmaceuticals Appoints Commercial Leadership Team

Lexicon Pharmaceuticals (NASDAQ:LXRX) has appointed a new commercial leadership team for its product candidate, telotristat ethyl. Members include Alexander Santini, Kiernan Seth and Gary Branch.
According to the press release:

Mr. Santini will have responsibility for all commercial activities in the United States for telotristat ethyl, an investigational oral drug for the treatment of carcinoid syndrome, with Dr. Seth and Mr. Branch reporting directly to him.

Alexander Santini has said the following:

“I am very excited to be leading the commercial team at this crucial juncture, and look forward to making telotristat ethyl commercially available to carcinoid syndrome patients following regulatory approval.”

Read the full press release here.